Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning
MJ Frank, AA Moustafa, HM Haughey… - Proceedings of the …, 2007 - National Acad Sciences
What are the genetic and neural components that support adaptive learning from positive
and negative outcomes? Here, we show with genetic analyses that three independent …
and negative outcomes? Here, we show with genetic analyses that three independent …
“Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans
EW Gunderson, HM Haughey… - … American journal on …, 2012 - Wiley Online Library
Cannabis, the most commonly used illicit substance, exerts its primary psychoactive effect
via delta‐9 tetrahydrocannabinol (Δ 9 ‐THC) agonism of cannabinoid receptor type 1 (CB1). …
via delta‐9 tetrahydrocannabinol (Δ 9 ‐THC) agonism of cannabinoid receptor type 1 (CB1). …
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
…, PEH Jackson, TD Bell, HM Haughey… - The lancet respiratory …, 2022 - thelancet.com
Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …
Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes
HM Haughey, E Marshall, JP Schacht, A Louis… - …, 2008 - Wiley Online Library
Aim To examine whether withdrawal after abstinence and cue‐elicited craving were associated
with polymorphisms within two genes involved in regulating the endocannabinoid system…
with polymorphisms within two genes involved in regulating the endocannabinoid system…
A survey of synthetic cannabinoid consumption by current cannabis users
EW Gunderson, HM Haughey, N Ait-Daoud… - Substance …, 2014 - journals.sagepub.com
Background Despite growing concern about the increased rates of synthetic cannabinoid (SC)
use and their effects, only limited data are available that addresses these issues. This …
use and their effects, only limited data are available that addresses these issues. This …
CHRNA4 and tobacco dependence: from gene regulation to treatment outcome
Context Given the probable importance of the α4 subunit of the neuronal nicotinic acetylcholine
receptor, the gene that codes for this subunit (CHRNA4) represents an excellent starting …
receptor, the gene that codes for this subunit (CHRNA4) represents an excellent starting …
Renin-angiotensin system modulation with synthetic angiotensin (1-7) and angiotensin II type 1 receptor–biased ligand in adults with COVID-19: two randomized …
…, J Mason, PEH Jackson, RW Coleman, HM Haughey… - Jama, 2023 - jamanetwork.com
Importance Preclinical models suggest dysregulation of the renin-angiotensin system (RAS)
caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II …
caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II …
Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function
AE Fleckenstein, HM Haughey, RR Metzger… - European journal of …, 1999 - Elsevier
High-dose administrations of amphetamine, methamphetamine, cathinone, methcathinone
or methylenedioxymethamphetamine rapidly decrease dopamine and serotonin transporter …
or methylenedioxymethamphetamine rapidly decrease dopamine and serotonin transporter …
Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia
RR Metzger, HM Haughey, DG Wilkins, JW Gibb… - … of Pharmacology and …, 2000 - ASPET
Single and multiple high-dose administrations of methamphetamine (METH) differentially
decrease dopamine (DA) transporter (DAT) function, as assessed by measuring [ 3 H]DA …
decrease dopamine (DA) transporter (DAT) function, as assessed by measuring [ 3 H]DA …
Safety and efficacy of dupilumab for the treatment of hospitalized patients with moderate to severe coronavirus disease 2019: a phase 2a trial
…, AN Donlan, JZ Ma, HM Haughey… - Open Forum …, 2022 - academic.oup.com
Background Based on studies implicating the type 2 cytokine interleukin 13 (IL-13) as a
potential contributor to critical coronavirus disease 2019 (COVID-19), this trial was designed as …
potential contributor to critical coronavirus disease 2019 (COVID-19), this trial was designed as …